Anavex Life Sciences

Anavex successfully completes phase I Alzheimer’s trial

Monday, November 14, 2011

Anavex Life Sciences has successfully completed its phase I single ascending dose (SAD) clinical trial of ANAVEX 2-73, the company’s lead drug candidate for the treatment of Alzheimer’s Disease.  ANAVEX 2-73 is the first of a new class of oral drugs being studied to potentially treat AD through disease modification rather than focusing only on symptomatic improvement.

[Read More]

Anavex continues ANAVEX 2-73 phase I trial

Friday, July 8, 2011

Anavex Life Sciences has commenced the 30mg dose step in its ongoing phase I clinical trial to evaluate ANAVEX 2-73, a drug candidate for Alzheimer’s disease. This is the third of six potential dose steps and follows the successful completion of the 1mg and 10mg dosing rounds.  There have been no adverse effects recorded to date.

[Read More]